Roche Holding AG (RHHVF)
336.62
+11.07 +3.40%
OTC Markets
May 14, 15:40
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 62.52B |
| Revenue (Annual YoY Growth) | Upgrade |
| EPS Diluted (TTM) | 17.64 |
| EPS Diluted (Annual YoY Growth) | Upgrade |
| Net Income (TTM) | 15.26B |
| Profitability | |
| Gross Profit Margin | Upgrade |
| Profit Margin | Upgrade |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 2.93% |
| Price and Valuation | |
| Market Cap | 287.18B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 4.658 |
| PE Ratio | 19.09 |
| Price to Book Value | 6.904 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Annual) | Upgrade |
| Free Cash Flow | 12.87B |
| Return on Equity | Upgrade |
View All RHHVF News
News
-
WireHeadlineTime (ET)
-
SA Breaking News11/03 10:44
-
SA Breaking News09/06 11:53
-
PR Newswire05/25 01:00
-
SA Breaking News03/02 06:30
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 10/15/2021 00:00 | Earnings Calls | Q3 2021 Earnings Call |
| 07/23/2021 00:00 | Earnings Results | Q2 2021 Earnings Results |
| 03/18/2021 | Dividends | 9.866 Normal dividend, declared February 04, 2021 and paid March 22, 2021 |
| 02/04/2021 01:00 EST | Earnings Results | Q4 2020 Earnings Results |
| 02/04/2021 08:00 EST | Earnings Calls | Q4 2020 Earnings Call |
| 10/15/2020 00:00 | Earnings Results | Q3 2020 Earnings Results |
| 10/15/2020 00:00 | Earnings Calls | Q3 2020 Earnings Call |
| 07/23/2020 00:00 | Earnings Results | Q2 2020 Earnings Results |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- Description: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 60% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
- URL: https://www.roche.com
- Investor Relations URL: https://www.roche.com/investors.htm
- HQ State/Province: N/A
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Equity Style: Large Cap/Blend
- Next Earnings Release: Jul. 23, 2021
- Last Earnings Release: Feb. 04, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: Mar. 18, 2021
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 336.62 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| IGI963 | IG Mackenzie European Equity J NL | 3.91% |
| TGADX | Templeton Growth Adv | 3.15% |
| TEWTX | Templeton World C | 3.12% |
| GQLFX | GMO Quality V | 2.28% |
| TIEHX | TIAA-CREF International Eq Advisor | 1.89% |
| TCIHX | TIAA-CREF International Eq Idx Advisor | 1.42% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- RHHVF Tweets Stocktwits
Advertisement
